Vaccine Development

Elizabeth A D Hammershaimb; James D Campbell

doi:10.1016/j.pcl.2024.01.018

Vaccine Development

Pediatr Clin North Am. 2024 Jun;71(3):529-549. doi: 10.1016/j.pcl.2024.01.018. Epub 2024 Mar 12.

Authors

Elizabeth A D Hammershaimb¹, James D Campbell²

Affiliations

¹ Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 West Baltimore Street, Room 480, Baltimore, MD 21201, USA; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: ehammershaimb@som.umaryland.edu.
² Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 West Baltimore Street, Room 480, Baltimore, MD 21201, USA; Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.

PMID: 38754940
DOI: 10.1016/j.pcl.2024.01.018

Abstract

This article considers ethical considerations surrounding pediatric vaccine development for pandemic preparedness, examines some historical cases of pediatric vaccines developed during past smallpox, influenza, and 2019 coronavirus disease pandemics, and discusses the current state of vaccine development for pandemic preparedness, including vaccines against smallpox/mpox, influenza, anthrax, and Ebola that are included in the US Strategic National Stockpile and vaccines being developed against priority pathogens identified by the World Health Organization.

Keywords: Anthrax; COVID-19; Ebola; Emerging infections; Influenza; Mpox; Pediatric vaccines; Smallpox.

Publication types

Review
Historical Article

MeSH terms

COVID-19 / epidemiology
COVID-19 / prevention & control
Child
Humans
Pandemics / prevention & control
United States
Vaccine Development*
Vaccines